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Introduction
The therapeutic peptide pipeline has expanded substantially in the last 30 years and new injectable peptides are constantly emerging [1] . Developing oral delivery systems for peptides is important in order to improve patient compliance and, in the case of selected anti-diabetic peptides, to provide a more physiological route of delivery than injection.
However, most peptides have unfavorable physicochemical properties for oral delivery including large molecular weight (MW), high hydrophilicity, a tendency to aggregate, susceptibility to pancreatic serine proteases, and low intestinal permeability [2] .
Salmon calcitonin (sCT, MW 3432), is a benchmark peptide to test any technology for oral delivery as it encompasses all five problems [2] . It is a second line anti-resorptive treatment for osteoporosis, as well as for Paget's disease and hypercalcemia, and is marketed in injectable and nasal formats [3] . Its commercial viability for long term use in post-menopausal women has been questioned recently due to possible links to cancer, and regulatory agencies have now recommended only short term use given its relatively narrow risk-to-benefit profile [4] . The most advanced oral sCT formulation, TBRIA TM (Tarsa Therapeutics, PA, USA), contains the peptide in vesicles protected by citric acid (CA), which is released in the duodenum following erosion of a pH-dependent methacrylate-based polymeric coating. This formulation completed Phase III [5] and an New Drug Application was submitted to the FDA in 2015.
Drugs from delayed-release formulations of small molecules are released following passage through the stomach (e.g. Depakote (AbbVie, IL, USA) [6] ), whereas extendedrelease formulations deliver the drug partially after ingestion and then the remainder over an extended time-frame (e.g. Embeda ® (Pfizer, NY, USA) [7] ). Targeted release of drugs to selected regions of the GI tract can be achieved by coating solid dosages with enteric, time-dependent, or pH-dependent materials. The most common site for systemic delivery is to target the small intestine using enteric coated solid dosage forms with pHdependent polymers including poly(meth)acrylates: e.g. Eudragit ® (Evonik Rohm GmbH, Germany) [8] , and cellulose-based ones: e.g. hydroxypropylmethylcellulose,
acetate succinate and polyvinyl derivatives [9] . On the other hand, colonic drug delivery has attracted interest primarily for local delivery of small molecules to treat ulcerative colitis and colorectal cancer [10] . Similar to the small intestine, colonic delivery can be achieved by coating solid dosage forms with enteric polymers, but they require sufficient thickness to prevent premature release and are subject to high intrasubject variability. Budesonide MMX ® (multi-matrix system, Valeant, Bridgewater, NJ, USA) is a time-and pH-dependent delivery system consisting of enteric coated (Eudragit ® L) pellets with a rate-limiting polymer containing budesonide to permit extended release in the colon, which was recently approved for colitis patients by the FDA [11] . Other colonic targeting strategies include covalent linkage of a drug with a carrier (e.g. azo-, cyclodextrin-, glycoside-, glucuronide-conjugates), or delivery of intact drug embedded in biodegradable matrices /hydrogels, microemulsions, bioadhesive polymers, or in multiparticulates [12] .
We used an emulsion-based coated minisphere technology, the single multiple pill (SmPill ® , Sigmoid Pharma Ltd., Ireland), to test oral delivery of sCT with a view to providing data that could lead to establishment of a platform technology to release peptides in intestinal regions for systemic delivery. To our knowledge, there are no examples of a platform technology that can be modified with selected coatings and permeation enhancers (PEs) designed both to release a peptide in two different intestinal regions and to promote its subsequent permeation. Sodium caprate (C 10 ) and cocoglucoside (CG) were included in sCT-SmPill ® as PEs [13, 14] . Both molecules have a safe profile [15, 16] and history of use in man either in a rectal suppository (C 10 ), or in personal care products (CG) [13, 17] . The third molecule selected as a potential PE for sCT was sodium taurodeoxycholate (NaTDC) [18] , while citric acid (CA) was selected on the basis of a primary mechanism of action to protect sCT from serine proteases [19] .
In previous work, sCT-SmPill ® minispheres containing C 10 , CG, and NaTDC were efficacious and improved absolute bioavailability (F) of sCT following rat intra-jejunal (i.j.) and intra-colonic (i.c.) instillations [2] . The objectives of this work were firstly to develop suitable coatings for sCT-SmPill ® minispheres and then to use X-ray imaging to confirm delivery to rat jejunum and to rat colon following oral administration.
Secondly, we compared the associated pharmacokinetic (PK) and pharmacodynamic (PD) profiles for sCT delivered from minisphere formulations either (a) when instilled to jejunal or colonic regions in uncoated formats, or (b) when coated versions were administered by gavage. 
Material and methods

SmPill ® minisphere preparation with PEs
Minispheres were loaded with 60% (w/w) barium sulphate (BaSO 4 ) to enable X-ray detection. Minispheres were prepared by the methods of [2, 21] , but using only an aqueous phase. Formulations were prepared at 65°C by mixing milliQ ® water, gelatin, sorbitol, followed by addition of an oral suspension of 1 g/ml BaSO 4 . The gelatin melted and a clear solution was formed; samples were then equilibrated without stirring at 65°C for 1h. The solution was then extruded into cold Miglyol 810 ® to form minispheres. Minispheres were kept in Miglyol 810 ® at 2-8°C for 30 min, separated with a sieve and allowed to dry at 2-8°C for 7 days. Additional minisphere prototypes loaded with sCT were prepared using a water-in-oil emulsion method [2] . The theoretical percentage of each component in four dried minisphere formulation prototypes is shown ( Table 1 ). The typical diameter of dried minispheres was confirmed as 1-2 mm [2] . Wurster tube, and the coating agent was then sprayed through the nozzle resulting in a spray pattern concurrent with air feed. Minispheres were accelerated in the spray and dried due to the hot air while continuing in an upward path, before falling back into the tube for respraying. Minispheres were allowed to dry inside the tube for 5 min.
Minispheres coated with Eudragit ® were further cured for 1 h at 40°C, while minispheres coated with Surelease ® /Pectin were cured at 50°C, both yielding solid spheres with diameters of 1-2 mm. The pellet was then washed three times with cold PBS, and resuspended in 500µl of cell lysis buffer (from R&D cAMP kit). A freeze/thaw cycle was repeated twice to ensure cell lysis.
The theoretical loading of the four prototype formulations was approximately 2 mg sCT/100 mg minispheres (Table 1) , and individual calculations were carried for prototypes in order to allow the same concentration of minisphere-released sCT to be 
Rat intra-intestinal instillations
Male Wistar rats (Biotério Central UFRGS, Brazil) weighing 280-340g were housed under controlled environmental conditions with a 12:12 h light/dark cycle. Anaesthesia was induced as described above. Rats were euthanized at the end of experiments by overdosing with 0.5 ml of sodium thiopental. Absorption studies were carried out by instilling uncoated sCT-SmPill ® minispheres by the i.j. or i.c. routes at dose levels of ~2000 I.U. (~390µg) sCT/kg, according to [2] , with 6 rats per group Lower numbers of minispheres were instilled into each segment in the current study due to the higher loading achieved here compared to our previous instillation study [2] . 
Oral delivery of SmPill
Serum calcium and sCT analysis
Serum samples were thawed, vortexed and centrifuged at 5,000 g at 4ºC for 5 min to remove excess lipid layers. 60-100 μl serum samples were transferred to micro-tubes fitted with 85 mm tubes. In some cases, 0.9% NaCl was used as a diluent to expand the sample sizes when less than 60 μl serum was available. A fully automated Labmax 240 clinical chemical analyser (Labtest Diagnóstica SA, Brazil) was used for total calcium measurement (Reagent reference number: 95, Labtest Diagnóstica SA, Brazil). sCT was measured in rat serum using an extraction-free sCT ELISA (Cat. S-1155, Peninsula Laboratories, USA) with a detection limit of 25 ng/ml [2] . Absolute biovailability (F) was calculated in order to compare the the value (estimated from the area under the curve, AUC) obtained from extravascular delivery of sCT-SmPill ® with the value following intravenous (i.v.) dosing of sCT [26] . The relative F measured the bioavailability of sCT-SmPill ® formulation compared to the bioavailability of native sCT delivered by the same extravascular route.
Statistics
Statistical analysis was carried out using Prism-5 ® software (GraphPad ® , USA).
Unpaired Student's t-tests, ANOVA one-way repeated measurements, or two-way ANOVA with Dunnett's post-test were used as stated. Results are expressed as the mean ± SEM. A significant difference was considered to be present if P<0.05.
Results
Radiological experiments with barium-loaded minispheres in rats
Three minispheres coated with either Opadry ® white and Eudragit ® or with Opadry ® white and Surelease ® /Pectin were orally administered to rats on day 15 following the feeding protocol. For both formulations there was low inter-rat variability in terms of stomach-emptying time for the three minispheres. Five out of six rats in each group had no minispheres in the stomach after 2 h. Rats administered three Eudragit ® -coated minispheres emptied them from the stomach after 1 h, and these minispheres dissolved only after they reached the small intestine, confirming jejunal delivery (Fig. 1) . The X-ray data therefore suggests that minispheres coated with Opadry ® white and either Eudragit ® or Surelease ® /Pectin can be orally administered to rats and will dissolve in rat jejunum or colon respectively and may be suitable for achieving regional sCT release.
Analytical characterization of sCT-SmPill ® coated minispheres
The theoretical concentration of sCT in minisphere prototypes was slightly different from the concentration assayed by HPLC. This was probably due to variability in the formulation process associated with some sCT degradation. sCT-SmPill ® was prepared by adding a solution of sCT, prepared just before mixing to the previously-formed emulsion, and then a theoretical concentration of sCT per gram of minispheres was calculated. All sCT-SmPill ® minispheres were analysed for loading with same standard sCT solution of 0.1 mg/ml as a reference. Thus, a corresponding amount of minispheres were weighed out to obtain a theoretical final concentration of 0.1 mg/ml of sCT in solution (according to the theoretical potency described in Table 1 ). However, in the case of formulations containing CG and C 10 , the actual sCT concentrations were > 0.1 mg/ml. had higher sCT concentrations compared to their respective uncoated core. Therefore, it is likely that coatings provide protection to the sCT present in the core, in addition to the protection already provided by gelatin [2] . Dissolution of minispheres was first assessed in HCl (pH 1,0) for 2 h and then the minispheres were transferred to a modified PBS (pH 6.8) in order to simulate the pH change from dosages passing from the stomach to the small/large intestine. Minispheres with Eudragit ® coatings remained intact at acid pH, whereas they released all sCT within 3.5 h at pH 6.8 (Fig. 3A) , confirming the potential of this coating to release sCT in jejunum. Similarly, minispheres coated with Surelease ® /Pectin released no sCT at pH 1.0, but released all the sCT following a 24 h at pH 6.8 ( Fig. 3B) , thereby demonstrating delayed release and potential to release in the colon (Table 3) . however, to release more quickly according to the rate parameter (k) ( Table 2 ).
Regarding formulations designed for colonic delivery, times (t 0 ) to release 50% of sCT were determined as 4.6 and 7.2 h respectively for minispheres containing C 10 Table 2 were in accordance with analytical loading data.
Time ( Weibull function for each formulation was fitted. Weibull fitting is an empirical model, so it only estimates dissolution kinetics [27] . (Table 3) for all dissolutions profiles. Korsmeyer-Peppas is a simple relationship which described drug release from polymeric systems which relates a fraction of drug released (M t /M ∞ ) with the release rate constant (k) at a certain time (t) and the release exponent (n) [28] . In this model, the value of n characterizes the release mechanism of the drug. To calculate this value, only the portion of the release curve where M t / M ∞ < 0.6 was used [29] . Thus, new fitting of the data was carried out to obtain the parameters for the Korsmeyer-Peppas equation (Table 4 , Suppl. Fig 1) . Since n > 0.85, the mechanism which controlled the release of sCT from minispheres was the 'super case II transport' [30] . The dominant mechanism for sCT release from coated minispheres containing PEs was therefore diffusion through the coatings due to swelling of the gelatin and the polymeric matrix upon contact with dissolution media. 
Stability of sCT-SmPill ® coated minispheres
sCT-SmPill ® minispheres were kept at 5±3°C and monitored over 4 months in order to assess sCT stability. At each time point, minispheres were dissolved and released sCT was analysed by HPLC and by bioassay on T47D cells. The concentration of sCT in minispheres stored at 5°C had less than a 20% difference after 4 months for all formulations, except sCT-SmPill ® CG (j), which had a 40% reduction after month 2 (Table 5A) . This data suggests, that at the specific ratio between sCT and CG (1:14. retained > 85% of biological activity after 4 months at 5°C (Table 5B) . Overall, both types of analysis indicated good sCT stability in coated minispheres. Although a clear pattern such as obtained by HPLC analysis was not identified for T47D cells, sCT released from minispheres retained > 85% of biological activity after 4 months at 4°C (Table 5B) . 
Intestinal instillations of uncoated sCT-SmPill ® minispheres to rats
Intra-intestinal instillations of the uncoated sCT-SmPill ® minispheres were carried out in order to obtain PK and PD profiles of formulations (Table 6 , Fig.4 ). Minispheres were loaded with ~2% of sCT (w/w). The relative F of sCT-SmPill ® minispheres to native sCT by i.j. instillation was 2.1%, 1.4% and 1.2% for minispheres containing NaTDC, CG, and CA respectively. Although the presence of NaTDC yielded the maximal AUC, hypocalcaemia was more pronounced for minispheres containing CG (Fig. 4) . This may be related to the fact that sCT released from minispheres containing CG had a longer t 1/2 compared to those containing NaTDC (Table 6 ). Uncoated minispheres containing C 10 and CG gave absolute F values of 18.2±1.8% and 17.3±1.9% respectively when instilled by the i.c. route, an increase of 2.6 and 2.5 fold over native sCT. Hypocalcaemia proved that sCT delivered from each minisphere prototype was biologically active (Fig 4) . Results are mean±SEM, n=5-6. *P < 0.05 and ** P < 0.01 compared to native sCT instilled by the same route, presented in Table 6 (one way ANOVA for F and AUC 0-360 min, post-Dunnett's test). Table 6 . PK parameters of instillations of uncoated minispheres over 6 h. sCT solution/kg, were dosed to controls. Absolute F of intra-jejunal (i.j.) or intra-colonic (i.c.)
instillations was calculated relative to an i.v. dose of 800 I.U. sCT/kg, AUC (0 -∞) = 11261±900 min.ng/ml. *P < 0.05 and **P < 0.01 compared to native sCT instilled by the same route (oneway ANOVA for F and AUC 0-360 min, post-Dunnett's test). , the T max varied from 2.5 to 3 h, in accordance with the dissolution and X-ray imaging data. The maximum hypocalcaemic effect was observed at 2 h for minispheres containing CG and CA, and at 4 h for minispheres containing NaTDC.
Oral gavage of sCT-SmPill ® coated minispheres to rats
Here, no clear correlation between PD and PK data could be observed, and the only clear conclusion is that serum calcium decreases indicate that the sCT from formulations which entered rat circulation is biologically active.
The T max values of sCT released from orally-administered minispheres coated with Surelease ® /Pectin were 3 h and 5 h for formulations containing C 10 and CG respectively (Table 7) , suggesting successful colonic delivery and subsequent absorption of sCT.
Overall, sCT serum concentrations were lower for colonically-released formulations than for jejunal (Fig. 5) . sCT-SmPill Table 7 . PK parameters of oral administration native sCT or sCT-SmPill ® coated minispheres to rats. 
Discussion
In order to develop an effective formulation for oral sCT delivery, SmPill ® minispheres were prepared including selected PEs or a pH-modifying agent (CA) and then coated for release in rat jejunum or colon. In situ instillation studies in rats confirmed that NaTDC, C 10 and CG were effective as PEs in uncoated sCT-SmPill ® minispheres for intestinal delivery of sCT either in rat jejunal or colonic segments. Appropriate coatings were used to control the release of sCT from minispheres following gavage. Firstly, X-ray was used to investigate the segments of the rat GI in which minispheres would dissolve.
Techniques described on the literature for tracking of solid oral dosage forms in rodents include gamma scintigraphy [31] , magnetic resonance imaging (MRI) [32] , positron emission tomography (PET) [33] , micro-computerized tomography (μCT) [34] and Xray [35] . The latter was simple, cheap and offers simultaneous visualization of both capsule and the GI tract using contrast agents [35] . The passage of coated minispheres through the GI tract confirmed minisphere dissolution at the intended sites. This is a novel use of X-rays to track minisphere location and dissolution in rats for such a technology.
Gastric emptying issues are a major problem when working with oral solid dosage forms in rats and, along with the difficulty in making scaled-down formulations, these may account for the low number of such studies. Enteric-coated gelatin capsules of approximately 2.5 mm diameter were emptied from rat stomach between 2 and 8 h, but there was also high variability [36] . With the help of the pro-kinetic, metoclopramide, those capsules exited rat stomach earlier and more consistently [36] . Others demonstrated that 14 days of a fixed feeding regimen to rats led to an accelerated solid gastric emptying due to presence of inter-digestive gastric contractions, and also due to an increase in their maximal amplitude [37] . Plasma ghrelin levels, which regulate the occurrence of stomach contractions in rats, reached its plasma C max 30 min before feeding [37] . We hypothesised that a similar fixed-fed regimen would promote less variable gastric emptying of SmPill ® minispheres from the rat stomach.
Here, X-ray imaging showed consistent gastric emptying of three minispheres in rats with the 4 h feeding regimen, and confirmed the suitability of the selected coatings for regional delivery of sCT to jejunum and colon respectively. Minispheres coated with Eudragit ® L30 D55 started to dissolve and to release BaSO 4 as soon as the pH increased.
According to in vitro dissolution tests, the lag time after increasing the pH from 1.0 to 6.8 is approximately 30 min to detect 50% of sCT released, which reinforces the hypothesis that this formulation is suitable for jejunal release. Surelease ® /Pectin films combine the colon-specific degradation properties of pectin with the protective properties of the water-insoluble polymer, ethyl cellulose [38, 39] . Minispheres coated with Surelease ® /Pectin were detected in the rat colon by X-ray imaging just before disintegrating, demonstrating the suitability of this formulation for colonic release of sCT. Even though rat colonic microflora is not able to digest pectin (unlike in man), pectin is still resistant to proteases active in the upper GI tract of both species [40] . In addition, pectin is retained in the coating layer absorbing surrounding water, and swells to form water channels and facilitates dissolution.
In vitro release of sCT from minispheres was modelled with the Korsmeyer-Peppas equation, yielding an apparent diffusional exponent (n) > 0.85, which represents a swelling-controlled release system [30] . In these systems, the drug is dispersed within a glassy polymer, gelatin, in the SmPill ® . As the fluid enters gelatin, the glass transition of the gelatin is lowered allowing for relaxation of the macromolecular chains. sCT is able to diffuse out of the swollen area of the minisphere, but no diffusion occurs through the glassy polymer phase. The rate of drug release in this model is controlled by the velocity and position of the front dividing the glassy and rubbery portion of the polymer. Various drug delivery system can be modelled with Korsmeyer-Peppas kinetic model, for example the release of chondroitin sulphate from the hydrophilic HPMC tablets [41] , and theophylline released from wax matrix granules [42] . Overall, the Korsmeyer-Peppas model suggests that biological fluids induce swelling of coating layers and gelatin, channels are formed, which allow sCT to be released from minispheres. This provides mechanistic insight into how the minispheres may release sCT in biological media.
Evidence that the biological activity of sCT was retained after it was incorporated into plateau of approximately 70% of basal level [2, 43, 44] . Additional indications that the SmPill ® -released sCT retained biological activity was obtained in vitro using the cAMP cell bioassay [45] , which confirmed that the formulation process was mild [2] . This assay was also used in combination with HPLC assay to demonstrate four months stability for coated sCT-SmPill ® minispheres kept at 5±3°C. This is an advantage for the SmPill® process, since most literature suggests that sCT in aqueous solution is labile [46] . Furthermore, it suggests that this mild and scalable technology may be suitable for other peptides in addition to sCT.
To compensate for dilution in the GI tract, oral sCT dose levels need to be much higher than that for intra-intestinal instillations [47] . Another reason to increase the dose for oral gavage to 6000 I.U./kg versus 2000 I.U./kg for instillations was because sCT metabolism in the small intestinal lumen is dependent upon concentration [48] . It was necessary to increase the concentration of sCT in contact with the intestinal epithelium, but without increasing the number of minispheres administered, which was impractical and could reduce gastric emptying. Jejunal (i.j.) and colonic (i.c.) instillation of coated sCT-SmPill ® minispheres confirmed the similarity between PK and PD profiles of these formulations containing ~2% of sCT (w/w) with profiles obtained in previous work of formulations containing 0.4% (w/w) of sCT [2] . As a corollary, the concentration of NaTDC, C 10 , CG and CA combined with sCT had to be decreased in relation to previous formulations [2] in order to allow spherical minispheres to be formed. Oral delivery of three sCT-SmPill ® minisphere prototypes resulted in an enhancement in bioavailability compared to native sCT solution given by oral gavage. The best relative F achieved for oral delivery of coated sCT-SmPill ® minispheres was 2.7% (P<0.05) for SmPill ® -CG (j) versus sCT solution. In addition, hypocalcaemia confirmed the biological activity of released sCT from each orally-administered minisphere prototype.
A plausible explanation for lower absolute F values by oral gavage compared to those from intra-intestinal instillations for equivalent minisphere, is that according to in vitro dissolution data, the total concentration of sCT released in vivo at the time of C max on PK profiles was likely to be lower than 100% (at a dose of 6000 I.U. sCT/kg following oral gavage), and this will increase the variability of absorption. For jejunal release of sCT from SmPill ® minispheres, the concentration of sCT available was likely to be close to 6000 I.U./rat, which may explain the better performance of these formulations in vivo than formulations designed for colonic delivery of sCT. Some have shown that in vivo release of minispheres coated with Surelease ® /Pectin might be faster than in vitro [49] . However, for colonic minisphere formulations, in vitro dissolution profiles
showed that there was a lag time of 5 -7 h for 50% of sCT to be released, suggesting
that not all sCT loaded in the minispheres was available at the time that C max was reached. Additionally, it was observed that rats dosed with minispheres designed for colonic delivery excreted any food remaining in the GI tract at the end of experiments.
This was probably because rats in a fixed-feeding regimen were fasted for almost 20 h prior to experiments, but food was then allowed within 2 h of dosage. This had no implication for jejunally-released minispheres, but it may have caused an interaction with colonic release.
In addition, there is a possibility that the restricted feed regimen used to rats orally dosed with SmPill ® improved the gastric emptying of minispheres, but also may have increased the proteolytic enzymes activity. Digestive enzymes can adapt to a specific diet in terms of nutrient intake [50] . Moreover, circadian rhythms of specific digestive enzymes in the small intestine of rats were mainly affected by anticipatory period when rats expect to be fed other than the food intake properly [51] . Anticipatory activity effect was also observed in rats included in a restricted feeding schedule of 2 h daily over 21 days. In our study, we did not analyse proteolytic enzymes profile of rats included in the fixed feed protocol. However, assuming that minispheres were administered at the time that rats expected to be fed, the anticipatory activity may have increased the proteolytic activity in the small intestine, leading to increased degradation of sCT dosed orally compared to intra-intestinal instillations. Further investigation is likely to be performed in order to verify enzyme activity using the specific fixed-feed protocol of this work. Finally, we envisage further gavage studies with refined minispheres: here, three large minispheres were administered by oral gavage per rat, whereas smaller diameter minispheres with lower loading could permit administration of higher numbers overall, perhaps paving the way for a multi-particulate delivery system.
In summary, the PK results indicated that systemic absorption of sCT was successfully achieved across jejunal and colonic segments from oral delivery of coated SmPill ® minispheres to rats. Regarding formulations designed for jejunal release, the bioavailability data suggests that use of CG as a PE yielded a positive effect on sCT jejunal absorption. Whereas for coated minispheres intended for colonic release of sCT, C 10 inclusion led to oral F of sCT (1.7±0.5%), but this was not statistically increased over control. It is important to note that marketed nasal versions of peptides including sCT are estimated to have absolute F of ~1% [52] . To our knowledge there are just a few examples in the literature showing successful oral delivery of sCT to rats for regional absorption using solid dosage forms. Enteric-coated capsules containing sCT and CA administered by gavage to rats achieved F ranging from just 1.2-1.8%, depending on the amount of CA added [53] , similar to the 1.4% seen here for SmPill ® -CA minispheres coated with Eudragit ® . Furthermore, sCT entrapped in PHEA-graftpolymethacrylate aggregates, enabled a C max of 58 ng/ml to be detected following oral gavage to in rats at similar dose levels to the current study [54] . Regarding studies with humans, absolute bioavailabilities ranging from 0.5 to 1.4% were achieved in a Phase I trial using a tablet containing sCT and a caprylic acid derivative (Eligen ® technology,
Emisphere, USA) [55] . Two other Phase I trials for enteric-coated preparations combining sCT with CA and either taurodeoxycholic acid or lauryl carnitine showed an average absolute F of 0.03% and 0.38%, respectively [56] . The Eligen ® carrier, 5-CNAC showed greater efficacy in suppression of bone resorption compared to a marketed nasal formulation, but it still failed the primary endpoint in Phase III trial for osteoporosis [57] . No oral formulation of sCT has yet been approved by the FDA.
Conclusions
Suitable coatings for sCT-SmPill ® minispheres were developed in order to promote delayed release of sCT into either rat jejunum or colon, as confirmed by X-ray imaging.
Stability studies indicated that sCT was stable over four months at 5°C when entrapped in minispheres. In situ instillations demonstrated that increased absorption of sCT solution and sCT from uncoated minispheres occurred in colon compared to jejunum.
Among the PEs evaluated in coated minispheres by oral gavage, CG was the most effective in jejunally-delivering sCT compared to sCT solution, but considerable loss in PK was seen by oral gavage compared to regional instillations. 
